RMH Comprehensive Stroke Centre Thrombolysis and Stroke Units : The Evidence Professor Stephen Davis Royal Melbourne Hospital Comprehensive Stroke Centre.

Slides:

Advertisements

Similar presentations

3/28/2017© 2009, American Heart Association. All rights reserved.

Advertisements

UPDATE ON THROMBOLYTIC THERAPY Markku Kaste Department of Neurology Helsinki University Central Hospital (HUCH) University of Helsinki Markku Kaste Department.

Stroke Care. What has been achieved so far and what still needs doing? Tony Rudd.

Accomplishments in Stroke Care

TPA in Stroke: What's All the Fuss?. FERNE Brain Illness and Injury Course.

Thrombolysis for stroke in older people.

The NINDS rt-PA Stroke Trial Prior information(Pre-Clinical, Phase I Studies, etc) Thrombolytic canalization of occluded arteries may reduce the degree.

Hyperacute Stroke Treatment: Inclusion and Exclusion Criteria

Update on Anti-platelets Gabriel A. Vidal, MD Vascular Neurology Ochsner Medical Center October 14 th, 2009.

Disclosures: Maximo C. Kiok, M.D. Medical Director of Stroke Program Trinity Health System.

EM TREATMENT OF ACUTE STROKE Progress, Problems, Politics William G. Barsan, M.D. University of Michigan.

Emily O’Brien, MSPH Predoctoral Trainee February 16, 2010 The North Carolina Stroke Care Collaborative Clinical Outcomes among Stroke Patients Receiving.

Nick Rushworth Executive Officer Brain Injury Australia International Federation on Ageing 10th Global Conference on Ageing – Melbourne, May 4, 2010 FALLS-RELATED.

Maximizing IV Thrombolytic Therapy in Acute Ischemic Stroke Kamakshi Lakshminarayan, MD PhD Assistant Professor Neurology & Epidemiology University of.

Professor Abdus Samad MD FACC Karachi Institute of Heart Diseases Karachi, Pakistan May 1, 2010.

Anticoagulation in Acute Ischemic Stroke. TPA: Tissue Plasminogen Activator 1995: NINDS study of TPA administration Design: randomized, double blind placebo-controlled.

COMMIT/CCS-2 (ClOpidogrel & Metoprolol in Myocardial Infarction Trial)

TPA in Acute Ischemic Stroke: The NINDS Reanalysis & Meta-analysis Data Sidney Starkman, MD, FACEP.

T-PA in Treatment of Acute Stroke: What We Know From NINDS 2004 vs 2000 Sidney Starkman, MD Departments of Emergency Medicine and Neurology, UCLA UCLA.

FERNE/MEMC Session: Treating Ischemic Stroke in the 3 – 4

Edward P. Sloan, MD, MPH FERNE/EMA Session: Treating Ischemic Stroke Patients Using a 3 to 4.5 Hour tPA Window.

Stroke - the size of the problem. What is a stroke? What is a transient ischaemic attack? What is the size of the problem?

Healthcare for London is part of Commissioning Support for London – an organisation providing clinical and business support to London’s NHS. Healthcare.

Stroke Units Southern Neurology. Definition of a stroke unit A stroke unit can be defined as a unit with dedicated stroke beds and a multidisciplinary.

SYDNEY MEDICAL SCHOOL What do the IST-3 results mean for the elderly patient with acute stroke? Westmead Hospital Clinical School | George Institute for.

Supporting NHS Wales to Deliver World Class Healthcare All Wales Stroke Services Improvement Collaborative Learning Session One 21 st October 2009.

The third international stroke trial (IST-3) of rt-PA. Main Results II: IST3 in context of updated meta-analysis of the randomised trials. JM Wardlaw,

The third international stroke trial (IST-3) main results: primary and secondary outcomes among 3035 patients The IST3 collaborative group hospitals.

Corticosteroid Randomisation After Significant Head Injury.

Maximizing IV Thrombolytic Therapy in Acute Ischemic Stroke Kamakshi Lakshminarayan, MD PhD Assistant Professor Neurology & Epidemiology University of.

Evidence based stroke medicine. Evaluating treatments for acute ischaemic stroke -what works and what doesn’t? Professor Peter Sandercock.

What’s on the horizon? Peter Sandercock ESC Lisbon 23rd May 2012.

Thrombolysis in acute ischaemic stroke – Updated Cochrane Thrombolysis metaanalysis JM Wardlaw, V Murray, PAG Sandercock University of Edinburgh and Karolinska.

Rationale: Why do we still need a large trial? IST-3 The Third International Stroke Trial: National Coordinators’ Meeting 25 May 2005, Bologna Professor.

Tissue Plasminogen Activator for Acute Ischemic Stroke National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.

Evidence in the ED Byron Drumheller, MD Penn Emergency Medicine.

Evidence based stroke medicine. Evaluating treatments for acute ischaemic stroke -what works and what doesn’t? Professor Peter Sandercock.

AIRE: Acute Infarction Ramipril Efficacy study Purpose To determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart.

S afe I mplementation of T hrombolysis in S troke Slide presentation adapted from

The third international stroke trial (IST-3) effect of thrombolysis on outcomes at 18 months in 2348 patients in long-term follow- up cohort The IST3 collaborative.

The Acute Stroke Menu: Something off the Back Page Innovative ways to use IV t-pa and other assorted therapies available outside the standard treatment.

Acute Ischemic Stroke Treatments Patrick J. Ward, PA-S.

Mr X, 79 years old Admitted on 5/5/00 to WGH stroke unit Dense (0/5) right arm and leg paresis Aphasic CT scan excluded a bleed Given trial treatment (IST-3)

Thrombolysis for patients > 80 – a different view Peter Sandercock On behalf of the IST3 collaborative Group UKSF Glasgow 1 st December 2009.

EXERCISE AFTER STROKE Specialist Instructor Training Course L3 Stroke: the first few days Prof. Gillian Mead Reader and Consultant The University of Edinburgh.

Stroke is a Medical Emergency. Face Arm Speech Test Helps public recognise symptoms of stroke; Can they smile? Does one side droop? Can they lift both.

Logo Authors & Affiliations : Josep L Clua-Espuny (1), Teresa Forcadell-Arenas (1), Rosa Ripolles-Vicente (1), Panisello-Tafalla(1), Antonia González-Henares.

IST-3: What are the implications for rt-PA therapy? Peter Sandercock University of Edinburgh on behalf of the IST-3 collaborative group ESC Lisbon 23rd.

Long-term mortality and thrombolysis therapy after a first acute ischemic stroke: gender differences. Ebrictus II Study. Authors & Affiliations Clua-Espuny.

Thrombolysis for acute ischaemic stroke Clinical

Long-term clinical outcome following emergency MR-based reperfusion therapy for acute middle cerebral artery occlusion Department of Stroke Treatment,

Thrombolysis: The Evidence Barry Moynihan Stroke Physician, St. George’s Hospital SITS/BASP Thrombolysis Nursing Training Day March 26 th 2012.

以多重死因資料比較台灣美國腦中風併發吸入性肺炎之趨勢奇美醫學中心張嘉祐醫師. Stroke Statistics -- A Report From the American Heart Association Approximately 56% of stroke deaths in 2009.

Brain waves or brain drain Interactive case discussion Dr Jenny Vaughan and Dr Richard Perry Charing Cross Hospital Hammersmith Hospital Imperial College.

Sanaz Sakiani, MD Endocrinology Fellow Journal Club

Hemicraniectomy in Older Patients with Extensive Middle-Cerebral-Artery Stroke DESTINY II TRIAL Katherine Steele 7 April 2014.

Arch Intern Med. 2007;167(1): doi: /archinte Figure Legend:

Thrombectomy in Acute Stroke

SITS Monitoring Study SITS-MOST

Does Hyponatremia in Asphyxiated Newborn infants correlate with incidence of death or disability? 1Mohamed S. Elboraee, 1,2Ernest Phillipos, 4Leonora Hendson,

Setareh Omran, MD Vascular Neurology Fellow

Volume 14, Issue 5, Pages (May 2015)

ECASS-II: intravenous alteplase in acute ischaemic stroke

AMISTAD II: Study Design

Volume 379, Issue 9834, Pages (June 2012)

Thrombolysis for acute ischemic stroke

Volume 14, Issue 5, Pages (May 2015)

Update from education committee

Three outcome measures from the NINDS tPA trial

Jennifer E. Fugate, DO, Alejandro A. Rabinstein, MD

Presentation transcript:

RMH Comprehensive Stroke Centre Thrombolysis and Stroke Units : The Evidence Professor Stephen Davis Royal Melbourne Hospital Comprehensive Stroke Centre University of Melbourne

Stroke in Australia 53,000 per year 53,000 per year 15,000 per year with stroke or TIA in Victoria 15,000 per year with stroke or TIA in Victoria Mortality rate of 33% at 12 months Mortality rate of 33% at 12 months Higher than most forms of cancer Higher than most forms of cancer 3 rd most common cause death 3 rd most common cause death Commonest cause of serious adult disability Commonest cause of serious adult disability An increasing challenge with the ageing of our population An increasing challenge with the ageing of our population

Without acute reperfusion, strokes grow No Reperfusion Reperfusion

Time is brain – Quantified Saver J. Stroke 2006;37: RMH Comprehensive Stroke Centre

Comparison: tPA Vs Placebo Outcome: Death or dependency  3 hours ECASS I28 /4728 / (0.18, 1.23) ECASS II47 /8148 / (0.44, 1.58) NINDS179 / / (0.35, 0.68) ATLANTIS8 /2316 / (0.25, 2.14) Total 262 / / (0.42, 0.73) >3 to 6 hours ECASS I173 / / (0.55, 1.15) ECASS II197 / / (0.62, 1.18) ATLANTIS99 / / (0.66, 1.28) Total 469 / / (0.71, 1.04) tPAPlaceboOROR n/Nn/N(95% CI Fixed)(95% CI Fixed) tPA better Placebo better Thrombolysis RMH Comprehensive Stroke Centre

Comparison: tPA Vs Placebo (  3 hours) Outcome: Risk Mortality ECASS I13 /498 / (0.50, 3.70) ECASS II11 /816 / (0.65, 5.30) NINDS54 /31264 / (0.54, 1.21) ATLANTIS4 /232 / (0.64, 22.61) Total 82 /46580 / (0.72, 1.41) All intracranial haemorrhage ECASS I12 /492 / (1.22, 27.94) ECASS II7 /814 / (0.48, 6.15) NINDS34 /31211 / (1.66, 6.73) ATLANTIS3 /230 / (0.65,267.05) Total 56 /46517 / (1.98, 5.96) tPAPlaceboOROR n/Nn/N(95% CI Fixed)(95% CI Fixed) tPA betterPlacebo better Thrombolysis RMH Comprehensive Stroke Centre

Intravenous rt-PA stroke trials : pooled analysis Global outcome score (mRS, Barthel Index, glascow score at 90 days) The ATLANTIS, ECASS, AND NINDS rt-PA Study group, 2002 Stroke onset to treatment time (OTT) [min] Adjusted odds ratio Thrombolysis N = 2799 RMH Comprehensive Stroke Centre

Davis SM, Hand PJ, Donnan GA. MJA 2007;187:

MJA, 2003 RMH Comprehensive Stroke Centre

The Stroke Trialists' Collaboration BMJ, 1997 RMH Comprehensive Stroke Centre

For whom does SU work? Almost everyone! gender, age, severity All types of SCU that provide care lasting >1 week Benefit most apparent in units based in a discrete ward Not mobile teams Cochrane Library, 2003 RMH Comprehensive Stroke Centre

The effectiveness of SCU OutcomeStroke UnitControlRisk Difference Home44%38%6 (independent) Home16%16%0 (dependent) Institutional care18%20%-3 Dead21%25%-4 For every 100 patients receiving organised (stroke unit) care: 4 extra survive, 2 avoid NH care, 5 return home Reduction in length of stay by 6 days RMH Comprehensive Stroke Centre

Reduction in RMH stroke mortality due to Stroke Care Unit Fall %% Cerebral infarct Cerebral haemorrhagic RMH Comprehensive Stroke Centre

79% hospitals in NSF survey did not have Stroke Care Unit